thalidomide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2616	50-35-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: thalidomide (+/-)-Thalidomide thalomid	A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. Molecular weight: 258.23 Formula: C13H10N2O4 CLOGP: 0.53 LIPINSKI: 0 HAC: 6 HDO: 1 TPSA: 83.55 ALOGS: -2 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

thalidomide
(+/-)-Thalidomide
thalomid

A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.

Molecular weight: 258.23
Formula: C13H10N2O4
CLOGP: 0.53
LIPINSKI: 0
HAC: 6
HDO: 1
TPSA: 83.55
ALOGS: -2
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.05 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	22.13 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.95 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.40 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.70 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 16, 1998	FDA	CELGENE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Disease progression	2847.11	37.64	782	7232	16313	2333758
Death	2737.25	37.64	1108	6906	80360	2269711
Plasma cell myeloma	2601.31	37.64	627	7387	7506	2342565
Neuropathy peripheral	1279.64	37.64	386	7628	11046	2339025
Human chorionic gonadotropin increased	831.68	37.64	151	7863	335	2349736
Pneumonia	822.46	37.64	417	7597	48879	2301192
Malignant neoplasm progression	755.38	37.64	263	7751	11865	2338206
Deep vein thrombosis	511.28	37.64	201	7813	12731	2337340
Renal failure	490.10	37.64	212	7802	17137	2332934
Sepsis	435.65	37.64	199	7815	18289	2331782
Asthenia	420.36	37.64	265	7749	46661	2303410
Fatigue	356.44	37.64	303	7711	84570	2265501
Anaemia	312.25	37.64	197	7817	34595	2315476
Pulmonary embolism	308.25	37.64	156	7858	17927	2332144
Constipation	290.24	37.64	159	7855	21470	2328601
Fall	271.59	37.64	203	7811	46896	2303175
Haemoglobin decreased	261.72	37.64	140	7874	18011	2332060
Pancytopenia	252.85	37.64	118	7896	11334	2338737
Dyspnoea	252.73	37.64	242	7772	78491	2271580
Pyrexia	245.85	37.64	202	7812	53506	2296565
Dehydration	242.71	37.64	143	7871	22152	2327919
Respiratory failure	237.09	37.64	119	7895	13409	2336662
Oedema peripheral	231.70	37.64	142	7872	23621	2326450
Myelodysplastic syndrome	224.33	37.64	72	7942	2488	2347583
Thrombocytopenia	214.19	37.64	125	7889	19006	2331065
Unevaluable event	213.03	37.64	97	7917	8794	2341277
Dizziness	204.51	37.64	189	7825	58476	2291595
Thrombosis	194.90	37.64	92	7922	9052	2341019
Platelet count decreased	192.11	37.64	109	7905	15704	2334367
Hypoaesthesia	184.79	37.64	116	7898	20099	2329972
Febrile neutropenia	182.61	37.64	93	7921	10789	2339282
Cerebrovascular accident	182.42	37.64	115	7899	20071	2330000
Toxicity to various agents	179.17	37.64	137	7877	32617	2317454
Cardiac failure congestive	174.34	37.64	103	7911	15998	2334073
Pleural effusion	168.00	37.64	90	7924	11578	2338493
Vomiting	158.98	37.64	181	7833	71421	2278650
Hypotension	152.22	37.64	124	7890	32312	2317759
Plasma cell myeloma recurrent	151.49	37.64	35	7979	330	2349741
Cardiac disorder	149.25	37.64	73	7941	7760	2342311
Adverse drug reaction	148.33	37.64	74	7940	8209	2341862
Hip fracture	147.20	37.64	62	7952	4650	2345421
Acute myeloid leukaemia	146.20	37.64	53	7961	2657	2347414
Somnolence	141.14	37.64	104	7910	23381	2326690
Hepatosplenic T-cell lymphoma	137.66	37.64	24	7990	37	2350034
Paraesthesia	135.40	37.64	99	7915	21989	2328082
Syncope	134.77	37.64	89	7925	16786	2333285
Plasma cell leukaemia	129.03	37.64	27	7987	152	2349919
Acute kidney injury	126.63	37.64	105	7909	28017	2322054
Neutropenia	126.26	37.64	94	7920	21454	2328617
Plasmacytoma	123.73	37.64	30	7984	354	2349717
Atrial fibrillation	123.18	37.64	78	7936	13690	2336381
White blood cell count decreased	121.61	37.64	86	7928	18122	2331949
Chronic kidney disease	121.37	37.64	52	7962	4066	2346005
Nausea	121.18	37.64	200	7814	111989	2238082
Mucosal inflammation	118.79	37.64	55	7959	5169	2344902
Drug intolerance	118.46	37.64	76	7938	13641	2336430
Infection	113.15	37.64	82	7932	17947	2332124
Gastrointestinal haemorrhage	112.61	37.64	71	7943	12364	2337707
Hypoxia	109.59	37.64	55	7959	6172	2343899
Metastatic malignant melanoma	107.44	37.64	26	7988	304	2349767
Therapy non-responder	106.84	37.64	59	7955	8045	2342026
Urinary tract infection	105.01	37.64	97	7917	29845	2320226
Laboratory test abnormal	102.83	37.64	50	7964	5240	2344831
Full blood count decreased	101.38	37.64	44	7970	3549	2346522
Rash	100.14	37.64	131	7883	59427	2290644
Tremor	96.82	37.64	79	7935	20582	2329489
Human chorionic gonadotropin positive	95.71	37.64	17	7997	31	2350040
Diarrhoea	95.49	37.64	153	7861	83411	2266660
Neoplasm progression	93.38	37.64	45	7969	4623	2345448
Haematocrit decreased	90.55	37.64	43	7971	4275	2345796
Bradycardia	90.37	37.64	57	7957	9924	2340147
Posterior reversible encephalopathy syndrome	88.84	37.64	36	7978	2444	2347627
Chest pain	88.79	37.64	86	7928	28051	2322020
Cardiac failure	87.43	37.64	60	7954	12034	2338037
Hypercalcaemia	83.92	37.64	35	7979	2557	2347514
Chronic obstructive pulmonary disease	83.72	37.64	48	7966	7029	2343042
Metastases to central nervous system	83.24	37.64	33	7981	2115	2347956
Diverticulitis	82.85	37.64	40	7974	4125	2345946
Pregnancy test urine positive	81.77	37.64	14	8000	18	2350053
Varicella zoster virus infection	80.62	37.64	21	7993	337	2349734
Confusional state	79.80	37.64	76	7938	24268	2325803
Blood creatinine increased	77.89	37.64	53	7961	10480	2339591
Oedema	77.02	37.64	52	7962	10151	2339920
Product dose omission	73.47	37.64	90	7924	38167	2311904
Back pain	73.32	37.64	82	7932	31577	2318494
Pain	70.18	37.64	113	7901	61744	2288327
Failure to thrive	68.40	37.64	23	7991	919	2349152
Lung infiltration	68.05	37.64	29	7985	2235	2347836
Diverticular perforation	66.01	37.64	19	7995	449	2349622
Brain neoplasm malignant	65.65	37.64	16	7998	193	2349878
Human chorionic gonadotropin abnormal	65.27	37.64	12	8002	29	2350042
Sinusitis	64.68	37.64	57	7957	16469	2333602
Pain in extremity	64.40	37.64	89	7925	42451	2307620
Acute leukaemia	64.23	37.64	17	7997	291	2349780
Hypertension	63.56	37.64	71	7943	27290	2322781
Large intestinal ulcer perforation	63.31	37.64	10	8004	4	2350067
Growth failure	61.75	37.64	12	8002	43	2350028
Bacteraemia	61.57	37.64	25	7989	1705	2348366
Seizure	61.18	37.64	66	7948	24400	2325671
Blood albumin decreased	60.67	37.64	25	7989	1770	2348301
Multiple organ dysfunction syndrome	60.20	37.64	40	7974	7601	2342470
Mesenteric abscess	59.74	37.64	10	8004	10	2350061
Refractory cytopenia with multilineage dysplasia	58.88	37.64	11	8003	30	2350041
Gastrointestinal fungal infection	58.87	37.64	12	8002	58	2350013
Transient ischaemic attack	58.79	37.64	36	7978	5942	2344129
Herpes zoster	58.16	37.64	43	7971	9682	2340389
Spinal cord compression	57.17	37.64	18	7996	582	2349489
Basal cell carcinoma	57.07	37.64	27	7987	2660	2347411
Drug ineffective	56.97	37.64	138	7876	101486	2248585
Epstein-Barr viraemia	56.50	37.64	13	8001	120	2349951
Acute lymphocytic leukaemia	56.43	37.64	17	7997	473	2349598
Atelectasis	55.21	37.64	24	7990	1941	2348130
Enterococcal sepsis	54.52	37.64	13	8001	142	2349929
Pulmonary oedema	54.30	37.64	37	7977	7326	2342745
Complications of bone marrow transplant	53.99	37.64	11	8003	53	2350018
Bronchitis	53.05	37.64	47	7967	13667	2336404
Malaise	52.98	37.64	94	7920	55491	2294580
Nasal abscess	52.33	37.64	10	8004	32	2350039
Sinus polyp	52.25	37.64	11	8003	64	2350007
Staphylococcal infection	52.19	37.64	32	7982	5294	2344777
Abdominal pain	52.12	37.64	72	7942	34302	2315769
Osteonecrosis of jaw	51.55	37.64	37	7977	7959	2342112
Pneumonia fungal	51.39	37.64	15	7999	373	2349698
Peripheral sensory neuropathy	51.29	37.64	19	7995	1011	2349060
Pathological fracture	51.01	37.64	20	7994	1244	2348827
Bone lesion	50.97	37.64	17	7997	662	2349409
Pulmonary mycosis	50.41	37.64	12	8002	130	2349941
Peripheral swelling	50.29	37.64	51	7963	17546	2332525
Myelofibrosis	48.92	37.64	14	8000	324	2349747
Gait inability	48.91	37.64	32	7982	5923	2344148
Mucosal erosion	48.77	37.64	13	8001	229	2349842
Staphylococcal bacteraemia	48.73	37.64	16	7998	593	2349478
Weight decreased	48.46	37.64	63	7951	28308	2321763
Polyneuropathy	47.80	37.64	21	7993	1742	2348329
Stem cell transplant	47.22	37.64	14	8000	368	2349703
Amyloidosis	46.98	37.64	13	8001	265	2349806
Pregnancy test false positive	46.23	37.64	11	8003	119	2349952
Clostridium bacteraemia	46.15	37.64	9	8005	33	2350038
Decreased appetite	46.03	37.64	62	7952	28829	2321242
Protein total increased	45.85	37.64	14	8000	408	2349663
Loss of consciousness	45.80	37.64	50	7964	18717	2331354
Hypoglossal nerve paresis	45.25	37.64	8	8006	14	2350057
Colitis	45.17	37.64	29	7985	5197	2344874
Osteonecrosis	45.11	37.64	33	7981	7309	2342762
Balance disorder	45.04	37.64	37	7977	9710	2340361
Haemorrhage	45.03	37.64	39	7975	11000	2339071
Squamous cell carcinoma of skin	45.03	37.64	16	7998	755	2349316
Septic shock	44.00	37.64	32	7982	7022	2343049
Splenomegaly	43.76	37.64	19	7995	1532	2348539
Candida infection	43.65	37.64	23	7991	2850	2347221
Orthostatic hypotension	43.61	37.64	23	7991	2856	2347215
Myocardial infarction	43.54	37.64	49	7965	18964	2331107
Mental status changes	43.43	37.64	29	7985	5553	2344518
Muscle spasms	43.40	37.64	52	7962	21514	2328557
Respiratory distress	43.19	37.64	28	7986	5101	2344970
Prothrombin time prolonged	42.33	37.64	19	7995	1658	2348413
Hair follicle tumour benign	42.25	37.64	8	8006	24	2350047
Oral fungal infection	41.59	37.64	13	8001	410	2349661
Gait disturbance	41.55	37.64	52	7962	22493	2327578
Blood glucose increased	41.43	37.64	39	7975	12251	2337820
Pulmonary hypertension	40.81	37.64	27	7987	5091	2344980
Hepatic failure	40.55	37.64	28	7986	5661	2344410
Encephalitis viral	40.38	37.64	11	8003	211	2349860
Pneumothorax	39.42	37.64	20	7994	2292	2347779
Cytomegalovirus infection	39.19	37.64	21	7993	2692	2347379
Neutrophil count decreased	39.17	37.64	29	7985	6538	2343533
Renal disorder	39.02	37.64	25	7989	4463	2345608
Compression fracture	38.91	37.64	15	7999	891	2349180
Electrolyte imbalance	38.80	37.64	19	7995	2018	2348053
Cardiac arrest	38.57	37.64	41	7973	14889	2335182
Bone marrow failure	38.23	37.64	27	7987	5659	2344412
Cough	38.15	37.64	61	7953	33056	2317015
Malnutrition	37.92	37.64	18	7996	1785	2348286

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Disease progression	3885.99	39.76	1172	8920	16091	1720598
Death	3829.91	39.76	1769	8323	85674	1651015
Plasma cell myeloma	3051.09	39.76	863	9229	9151	1727538
Neuropathy peripheral	1152.35	39.76	405	9687	8848	1727841
Pneumonia	1134.87	39.76	645	9447	45537	1691152
Malignant neoplasm progression	971.04	39.76	401	9691	13757	1722932
Deep vein thrombosis	799.90	39.76	316	9776	9604	1727085
Pulmonary embolism	542.96	39.76	261	9831	12798	1723891
Renal failure	515.59	39.76	290	9802	19727	1716962
Sepsis	466.51	39.76	269	9823	19169	1717520
Constipation	454.15	39.76	242	9850	14758	1721931
Asthenia	407.69	39.76	307	9785	34363	1702326
Dyspnoea	369.15	39.76	344	9748	51715	1684974
Oedema peripheral	324.88	39.76	197	9895	15353	1721336
Pyrexia	310.13	39.76	297	9795	46103	1690586
Respiratory failure	308.74	39.76	186	9906	14319	1722370
Acute myeloid leukaemia	298.22	39.76	112	9980	2929	1733760
Unevaluable event	284.53	39.76	132	9960	5934	1730755
Anaemia	270.75	39.76	226	9866	29231	1707458
Fatigue	269.51	39.76	287	9805	50494	1686195
Thrombosis	254.66	39.76	131	9961	7390	1729299
Plasma cell myeloma recurrent	245.69	39.76	63	10029	423	1736266
Pancytopenia	245.03	39.76	147	9945	11210	1725479
Cardiac failure congestive	231.01	39.76	158	9934	15112	1721577
Myelodysplastic syndrome	223.71	39.76	93	9999	3196	1733493
Plasmacytoma	218.76	39.76	58	10034	451	1736238
Haemoglobin decreased	205.78	39.76	154	9938	16960	1719729
Dehydration	201.48	39.76	154	9938	17504	1719185
Fall	186.46	39.76	177	9915	27037	1709652
Dizziness	181.39	39.76	194	9898	34167	1702522
Basal cell carcinoma	178.28	39.76	73	10019	2410	1734279
Hypoaesthesia	175.79	39.76	113	9979	9722	1726967
Thrombocytopenia	168.41	39.76	150	9942	21099	1715590
Atrial fibrillation	168.38	39.76	130	9962	14981	1721708
Neutropenia	167.18	39.76	140	9952	18120	1718569
Squamous cell carcinoma of skin	163.87	39.76	57	10035	1185	1735504
Febrile neutropenia	153.99	39.76	109	9983	10991	1725698
Platelet count decreased	145.68	39.76	124	9968	16399	1720290
Hypotension	141.70	39.76	159	9933	29495	1707194
Neoplasm progression	137.39	39.76	66	10026	3201	1733488
Full blood count decreased	135.87	39.76	61	10031	2531	1734158
Syncope	134.52	39.76	111	9981	14058	1722631
Adverse drug reaction	133.30	39.76	73	10019	4665	1732024
Prostate cancer	129.38	39.76	71	10021	4555	1732134
Nausea	125.74	39.76	198	9894	50998	1685691
Paraesthesia	125.34	39.76	94	9998	10357	1726332
Myelofibrosis	121.96	39.76	35	10057	375	1736314
Chronic kidney disease	120.01	39.76	66	10026	4251	1732438
Cardiac disorder	119.47	39.76	81	10011	7610	1729079
Haematocrit decreased	117.89	39.76	65	10027	4208	1732481
Infection	117.65	39.76	97	9995	12263	1724426
Septic shock	115.59	39.76	81	10011	8028	1728661
White blood cell count decreased	114.45	39.76	98	9994	13051	1723638
Bradycardia	113.71	39.76	89	10003	10445	1726244
Metastases to central nervous system	112.84	39.76	46	10046	1499	1735190
Pleural effusion	111.64	39.76	90	10002	11020	1725669
Somnolence	110.87	39.76	107	9985	16632	1720057
Metastatic malignant melanoma	110.70	39.76	33	10059	408	1736281
Toxicity to various agents	110.63	39.76	139	9953	29002	1707687
Decreased appetite	108.84	39.76	125	9967	23746	1712943
Acute kidney injury	108.49	39.76	151	9941	34793	1701896
Confusional state	108.27	39.76	118	9974	21160	1715529
Myocardial infarction	106.95	39.76	132	9960	27042	1709647
Drug intolerance	106.62	39.76	69	10023	5993	1730696
Diarrhoea	103.84	39.76	187	9905	53665	1683024
Hypoxia	102.73	39.76	67	10025	5896	1730793
Spinal cord compression	100.61	39.76	34	10058	645	1736044
Type 2 lepra reaction	92.84	39.76	20	10072	53	1736636
Hip fracture	91.56	39.76	41	10051	1689	1735000
Chest pain	90.26	39.76	104	9988	19810	1716879
Rash	89.81	39.76	146	9946	38547	1698142
Malignant melanoma	87.84	39.76	39	10053	1574	1735115
Amyloidosis	86.58	39.76	26	10066	330	1736359
Therapy non-responder	85.59	39.76	61	10031	6205	1730484
Vomiting	85.44	39.76	142	9950	38173	1698516
Chronic obstructive pulmonary disease	83.73	39.76	59	10033	5894	1730795
Plasma cell leukaemia	83.29	39.76	22	10070	168	1736521
Cellulitis	81.58	39.76	60	10032	6408	1730281
Staphylococcal infection	81.34	39.76	53	10039	4654	1732035
Gastrointestinal haemorrhage	81.15	39.76	84	10008	14183	1722506
Failure to thrive	81.03	39.76	33	10059	1072	1735617
Metastasis	78.94	39.76	30	10062	808	1735881
Cardiac failure	78.61	39.76	78	10014	12524	1724165
Diverticulitis	74.27	39.76	39	10053	2286	1734403
Mental status changes	73.57	39.76	55	10037	6020	1730669
Cough	71.84	39.76	91	10001	19106	1717583
Pneumonitis	67.44	39.76	44	10048	3871	1732818
Diverticular perforation	67.06	39.76	23	10069	457	1736232
Hypercalcaemia	67.05	39.76	34	10058	1852	1734837
Oedema	67.04	39.76	55	10037	6893	1729796
Pathological fracture	66.29	39.76	24	10068	562	1736127
Leukaemia	66.03	39.76	26	10066	772	1735917
Prostate cancer metastatic	65.52	39.76	27	10065	904	1735785
Laboratory test abnormal	65.49	39.76	45	10047	4314	1732375
General physical health deterioration	63.61	39.76	71	10021	13047	1723642
Pregnancy of partner	63.47	39.76	18	10074	184	1736505
Lung infiltration	62.72	39.76	34	10058	2125	1734564
Cerebrovascular accident	62.61	39.76	82	10010	17784	1718905
Back pain	62.53	39.76	79	10013	16534	1720155
Acute leukaemia	60.57	39.76	20	10072	352	1736337
Cardiac arrest	60.35	39.76	76	10016	15854	1720835
Orthostatic hypotension	60.17	39.76	39	10053	3392	1733297
Pain	59.61	39.76	99	9993	26558	1710131
Bacteraemia	58.52	39.76	31	10061	1849	1734840
Colitis	57.77	39.76	41	10051	4139	1732550
Atelectasis	57.70	39.76	31	10061	1903	1734786
Multiple organ dysfunction syndrome	57.23	39.76	57	10035	9185	1727504
Renal disorder	56.29	39.76	40	10052	4046	1732643
Neutropenic sepsis	56.28	39.76	28	10064	1464	1735225
Enterococcal infection	56.27	39.76	24	10068	877	1735812
Staphylococcal bacteraemia	55.90	39.76	23	10069	767	1735922
Hepatic failure	55.42	39.76	46	10046	5857	1730832
Blood sodium decreased	55.27	39.76	32	10060	2272	1734417
Pulmonary oedema	55.03	39.76	48	10044	6538	1730151
Pain in extremity	54.48	39.76	78	10014	18394	1718295
Pneumonia aspiration	53.56	39.76	43	10049	5223	1731466
Lung neoplasm malignant	52.97	39.76	35	10057	3144	1733545
Brain neoplasm malignant	51.90	39.76	15	10077	165	1736524
Chills	51.15	39.76	60	10032	11627	1725062
Urinary tract infection	51.02	39.76	56	10036	10097	1726592
Drug ineffective	50.94	39.76	157	9935	63644	1673045
Sinusitis	49.65	39.76	41	10051	5182	1731507
Condition aggravated	49.21	39.76	80	10012	21070	1715619
Bone pain	48.83	39.76	34	10058	3328	1733361
Stem cell transplant	48.65	39.76	18	10074	449	1736240
Peripheral sensory neuropathy	47.46	39.76	21	10071	840	1735849
Renal cell carcinoma	47.32	39.76	25	10067	1483	1735206
Tremor	47.12	39.76	61	10031	13070	1723619
Dialysis	46.31	39.76	29	10063	2375	1734314
Hyperglycaemia	45.90	39.76	39	10053	5126	1731563
Muscular weakness	45.48	39.76	53	10039	10196	1726493
Fluid retention	45.02	39.76	34	10058	3775	1732914
Cardio-respiratory arrest	44.52	39.76	50	10042	9243	1727446
Osteonecrosis	43.83	39.76	34	10058	3928	1732761
Bone marrow failure	43.64	39.76	38	10054	5162	1731527
Prothrombin time prolonged	42.88	39.76	24	10068	1597	1735092
Blood albumin decreased	42.51	39.76	24	10068	1624	1735065
Skin ulcer	42.39	39.76	29	10063	2759	1733930
Mucosal inflammation	42.30	39.76	34	10058	4135	1732554
Squamous cell carcinoma	42.28	39.76	25	10067	1846	1734843
Lethargy	42.07	39.76	43	10049	7141	1729548
Acute lymphocytic leukaemia	42.00	39.76	17	10075	543	1736146
Polyneuropathy	41.10	39.76	24	10068	1731	1734958
Spinal compression fracture	40.80	39.76	19	10073	857	1735832
Abdominal pain	40.43	39.76	74	10018	21416	1715273
Balance disorder	40.01	39.76	38	10054	5774	1730915
Blood creatinine increased	39.80	39.76	58	10034	13888	1722801

Pharmacologic Action:

Source	Code	Description
ATC	L04AX02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Other immunosuppressants
FDA PE	N0000008663	Decreased Immunologically Active Molecule Activity
CHEBI has role	CHEBI:35705	immunosuppressive agent
CHEBI has role	CHEBI:35816	leprostatic drug
CHEBI has role	CHEBI:48422	angiogenesis inhibitor
CHEBI has role	CHEBI:35623	anticonvulsant
CHEBI has role	CHEBI:50919	antiemetic
CHEBI has role	CHEBI:35717	sedative
CHEBI has role	CHEBI:35472	anti-inflammatory drug
CHEBI has role	CHEBI:35610	antineoplastic agent
MeSH PA	D020533	Angiogenesis Inhibitors
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D006131	Growth Inhibitors
MeSH PA	D006133	Growth Substances
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007166	Immunosuppressive Agents
MeSH PA	D007917	Leprostatic Agents
MeSH PA	D009676	Noxae
MeSH PA	D013723	Teratogens

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Multiple myeloma	indication	109989006	DOID:9538
Erythema nodosum leprosum	indication	240411003
Discoid lupus erythematosus	off-label use	200938002
Actinic prurigo	off-label use	201015007
Graft-versus-host disease	off-label use	234646005
Erosive oral lichen planus	off-label use	238662007
Subacute cutaneous lupus erythematosus	off-label use	239891002
Recurrent aphthous ulcer	off-label use	398870000
Prevention of Recurrent Aphthous Stomatitis	off-label use
Orthostatic hypotension	contraindication	28651003
Bradycardia	contraindication	48867003
Epilepsy	contraindication	84757009	DOID:1826
Deep venous thrombosis	contraindication	128053003
Pulmonary thromboembolism	contraindication	233935004
Pregnancy, function	contraindication	289908002
Peripheral nerve disease	contraindication	302226006
Neutropenic disorder	contraindication	303011007	DOID:1227
Thromboembolic disorder	contraindication	371039008
Breastfeeding (mother)	contraindication	413712001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.84	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6315720	Oct. 23, 2020	METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6315720	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6561977	Oct. 23, 2020	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6561977	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6755784	Oct. 23, 2020	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6755784	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6869399	Oct. 23, 2020	ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6869399	Oct. 23, 2020	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6869399	Oct. 23, 2020	MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6869399	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	7141018	Oct. 23, 2020	ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	7141018	Oct. 23, 2020	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	7141018	Oct. 23, 2020	MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	7141018	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	7959566	Oct. 23, 2020	USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	8315886	Oct. 23, 2020	TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
100MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	8626531	Oct. 23, 2020	USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE
150MG	THALOMID	CELGENE	N020785	Jan. 10, 2007	RX	CAPSULE	ORAL	6315720	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
150MG	THALOMID	CELGENE	N020785	Jan. 10, 2007	RX	CAPSULE	ORAL	6561977	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
150MG	THALOMID	CELGENE	N020785	Jan. 10, 2007	RX	CAPSULE	ORAL	6755784	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
150MG	THALOMID	CELGENE	N020785	Jan. 10, 2007	RX	CAPSULE	ORAL	6869399	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
150MG	THALOMID	CELGENE	N020785	Jan. 10, 2007	RX	CAPSULE	ORAL	7141018	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
150MG	THALOMID	CELGENE	N020785	Jan. 10, 2007	RX	CAPSULE	ORAL	7959566	Oct. 23, 2020	USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
150MG	THALOMID	CELGENE	N020785	Jan. 10, 2007	RX	CAPSULE	ORAL	8315886	Oct. 23, 2020	TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
150MG	THALOMID	CELGENE	N020785	Jan. 10, 2007	RX	CAPSULE	ORAL	8626531	Oct. 23, 2020	USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6315720	Oct. 23, 2020	METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6315720	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6561977	Oct. 23, 2020	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6561977	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6755784	Oct. 23, 2020	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6755784	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6869399	Oct. 23, 2020	ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6869399	Oct. 23, 2020	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6869399	Oct. 23, 2020	MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	6869399	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	7141018	Oct. 23, 2020	ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	7141018	Oct. 23, 2020	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	7141018	Oct. 23, 2020	MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	7141018	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	7959566	Oct. 23, 2020	USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	8315886	Oct. 23, 2020	TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
200MG	THALOMID	CELGENE	N020785	Jan. 17, 2003	RX	CAPSULE	ORAL	8626531	Oct. 23, 2020	USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	6315720	Oct. 23, 2020	METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	6315720	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	6561977	Oct. 23, 2020	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	6561977	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	6755784	Oct. 23, 2020	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	6755784	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	6869399	Oct. 23, 2020	ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	6869399	Oct. 23, 2020	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	6869399	Oct. 23, 2020	MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	6869399	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	7141018	Oct. 23, 2020	ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	7141018	Oct. 23, 2020	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	7141018	Oct. 23, 2020	MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	7141018	Oct. 23, 2020	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	7959566	Oct. 23, 2020	USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	8315886	Oct. 23, 2020	TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
50MG	THALOMID	CELGENE	N020785	July 16, 1998	RX	CAPSULE	ORAL	8626531	Oct. 23, 2020	USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Protein cereblon	Cytosolic other	Q96SW2	CRBN_HUMAN	MODULATOR	EC50	6.39	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Tumor necrosis factor	Cytokine	P01375	TNFA_HUMAN		IC50	8	WOMBAT-PK
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN		IC50	6.43	WOMBAT-PK
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN		IC50	6.30	WOMBAT-PK
Prostaglandin G/H synthase 2	Enzyme		PGH2_SHEEP		IC50	6.30	CHEMBL
Prostaglandin G/H synthase 1	Enzyme		PGH1_SHEEP		IC50	6.43	CHEMBL

External reference:

ID	Source
4021134	VUID
N0000148588	NUI
C0039736	UMLSCUI
D00754	KEGG_DRUG
4Z8R6ORS6L	UNII
762	INN_ID
404878004	SNOMEDCT_US
4021134	VANDF
10432	RXNORM
78702007	SNOMEDCT_US
7488	MMSL
d04331	MMSL
005933	NDDF
CHEBI:9513	CHEBI
CHEMBL468	ChEMBL_ID
DB01041	DRUGBANK_ID
5426	PUBCHEM_CID
D013792	MESH_DESCRIPTOR_UI
7327	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Thalomid	HUMAN PRESCRIPTION DRUG LABEL	1	59572-205	CAPSULE	50 mg	ORAL	NDA	22 sections
Thalomid	HUMAN PRESCRIPTION DRUG LABEL	1	59572-210	CAPSULE	100 mg	ORAL	NDA	22 sections
Thalomid	HUMAN PRESCRIPTION DRUG LABEL	1	59572-215	CAPSULE	150 mg	ORAL	NDA	22 sections
Thalomid	HUMAN PRESCRIPTION DRUG LABEL	1	59572-220	CAPSULE	200 mg	ORAL	NDA	22 sections